PerpEquities

Laporan laba rugi Revolution Medicines, Inc. (RVMD)

NASDAQ · Healthcare · Biotechnology · Karyawan: 883 · CEO: Mark A. Goldsmith

Harga
$191,31 +0,55%
Kapitalisasi pasar
$41 M
Nilai perusahaan
$40,8 M
Laporan terakhir
Q2 '26 diajukan 2026-08-05
Laporan berikutnya
2026-11-04 Estimasi EPS: -$2,35

Revolution Medicines, Inc. (RVMD) untuk Q2 '26: pendapatan $0 (– yoy), laba operasional -$505 jt (– dari pendapatan), laba bersih -$644 jt. Dalam empat kuartal terakhir pendapatan mencapai $0.

Laporan laba rugi

Laporan laba rugiTrenQ3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Pendapatan$0$742 rb$0$0$0$0$0$0$0$0$0$0
Beban pokok pendapatan$0$0$0$0$0$0$0$0$0$4,7 jt$4,54 jt$0
Laba kotor$0$742 rb$0$0$0$0$0$0$0-$4,7 jt-$4,54 jt$0
Riset & pengembangan$108 jt$148 jt$118 jt$135 jt$152 jt$188 jt$206 jt$224 jt$263 jt$293 jt$344 jt$395 jt
Umum & administrasi$15,5 jt$32,2 jt$22,8 jt$21,7 jt$24 jt$28,2 jt$35 jt$40,6 jt$52,8 jt$64,3 jt$101 jt$110 jt
Beban operasional lainnya$0$0$0$0$0$0$0$0$0$0-$4,54 jt$0
Beban operasional$123 jt$181 jt$141 jt$157 jt$176 jt$216 jt$241 jt$265 jt$315 jt$357 jt$441 jt$505 jt
Laba operasional-$123 jt-$180 jt-$141 jt-$157 jt-$176 jt-$216 jt-$241 jt-$265 jt-$315 jt-$362 jt-$445 jt-$505 jt
Pendapatan bunga$10,9 jt$18,7 jt$23,8 jt$21,5 jt$20,4 jt$21,2 jt$24,9 jt$22,4 jt$22,1 jt$21,3 jt$19,5 jt$35,6 jt
Beban bunga$0$0$0$0$0$0$0$0$11,4 jt$11,9 jt$12,2 jt$23,8 jt
Pendapatan non-operasional lainnya (keuntungan investasi, kurs ...)-$10,9 jt-$47,6 jt-$24,9 jt-$23,4 jt-$19,4 jt-$21 jt-$27,3 jt-$16,9 jt-$21,5 jt-$8,67 jt-$3,6 jt$115 jt
Total pendapatan non-operasional$10,9 jt$18,8 jt$24,9 jt$23,4 jt$19,4 jt$21 jt$27,3 jt$16,9 jt$10,1 jt-$3,27 jt-$8,59 jt-$139 jt
Laba sebelum pajak-$112 jt-$161 jt-$116 jt-$133 jt-$156 jt-$195 jt-$213 jt-$248 jt-$305 jt-$365 jt-$454 jt-$644 jt
Pajak penghasilan-$3,87 jt$343 rb$0$0$0-$753 rb$0$0$0$0$0$0
Laba bersih-$108 jt-$162 jt-$116 jt-$133 jt-$156 jt-$195 jt-$213 jt-$248 jt-$305 jt-$365 jt-$454 jt-$644 jt
EPS (dasar)-$0,99-$1,14-$0,70-$0,81-$0,94-$1,13-$1,13-$1,31-$1,61-$1,90-$2,29-$3,06
EPS (dilusian)-$0,99-$1,14-$0,70-$0,81-$0,94-$1,13-$1,13-$1,31-$1,61-$1,90-$2,29-$3,06
Saham (dasar, rata-rata tertimbang)109 jt141 jt165 jt165 jt167 jt168 jt188 jt188 jt189 jt190 jt198 jt211 jt
Saham (dilusian, rata-rata tertimbang)109 jt141 jt165 jt165 jt167 jt168 jt188 jt188 jt189 jt190 jt198 jt211 jt
Depresiasi & amortisasi$2,15 jt$2,86 jt$2,76 jt$2,8 jt$2,88 jt$3,39 jt$3,72 jt$3,8 jt$4,34 jt$4,7 jt$4,54 jt$4,5 jt
EBITDA-$110 jt-$130 jt-$113 jt-$130 jt-$153 jt-$192 jt-$210 jt-$244 jt-$289 jt-$348 jt-$437 jt-$616 jt

Distandardisasi oleh Financial Modeling Prep dari laporan perusahaan; arus keluar dan biaya mempertahankan tanda yang dilaporkan penyedia. Arahkan kursor ke periode untuk melihat tanggal berakhirnya. Jumlah dalam USD.

Pendapatan, laba operasional, dan pertumbuhan

kuartalan

Margin

kuartalan

Biaya sebagai % pendapatan

kuartalan

Laporan lainnya

Sumber

Laporan keuangan, pendapatan segmen, metrik, estimasi: Financial Modeling Prep. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30

Data per 2026-11-02